IL2 and uveal melanoma: Concluding from a meta-analysis involving 13 trials (published from 1988 to 2016), TIL+ recombinant IL-2 treatment for metastatic melanoma, excluding uveal melanoma, was found to have an ORR of 41% and an overall complete response rate (CRR) of 12%.